경남제약

053950KOSDAQ

56.5 / 100

Reference Date: 2026-10-23

Financial Score20.0 / 40

News Sentiment12.5 / 25

Momentum10.0 / 20

Disclosure14.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 22.1% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Gyeongnam Pharmaceutical primarily operates in the manufacturing and sales of pharmaceuticals, raw materials, and health functional foods, distributing products like Lemona, Jaha Saengryeok, and Minol. In 2025, revenue reached 55.9 billion won, a decrease of approximately 8% compared to the previous period, though the Lemona food product line continues to show steady growth. The company is expanding its business through online marketing and broadening its distribution channels.

Number of Employees

238people

Average Salary

53.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

0.32Industry Average 1.207.0Point

Half of industry avg (excellent)

ROE

-8.06Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

1.01Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20251.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼9.6% (2-year basis)

Operating Profit Growth Rate

1.0 / 3

Avg ▲1.2% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -7.9% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position5.0Point

52w mid range (44%)

Current 1,791Won52-week high 3,35052-week low 564

1-month return0.0Point

1m -22.13% (strong drop)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

3 totalPositive 2Neutral 1Negative 0

Neutral철회신고서2026-10-12
Positive[기재정정]주요사항보고서(유상증자결정)2026-10-12
Positive기타주요경영사항 (유상증자결정(주주배정증자)-철회)2026-10-12